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Guideline Adherence as a Function of Patient Risk
An End to Paradoxical Care?
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Objectives The goals of this analysis were to determine: 1) whether guideline-based care during hospitalization for a myo-
cardial infarction (MI) varied as a function of patients’ baseline risk; and 2) whether temporal improvements in
guideline adherence occurred in all risk groups.
Background Guideline-based care of patients with MI improves outcomes, especially among those at higher risk. Previous
studies suggest that this group is paradoxically less likely to receive guideline-based care (risk–treatment
mismatch).
Methods A total of 112,848 patients with MI were enrolled at 279 hospitals participating in Get With The Guidelines–
Coronary Artery Disease (GWTG–CAD) between August 2000 and December 2008. We developed and validated
an in-hospital mortality model (C-statistic: 0.75) to stratify patients into risk tertiles: low (0% to 3%), intermedi-
ate (3% to 6.5%), and high (6.5%). Use of guideline-based care and temporal trends were examined.
Results High-risk patients were significantly less likely to receive aspirin, beta-blockers, angiotensin-converting inhibi-
tors/angiotensin receptor blockers, statins, diabetic treatment, smoking cessation advice, or cardiac rehabilita-
tion referral at discharge compared with those at lower risk (all p  0.0001). However, use of guideline-
recommended therapies increased significantly in all risk groups per year (low-risk odds ratio: 1.33 [95%
confidence interval (CI): 1.22 to 1.45]; intermediate-risk odds ratio: 1.30 [95% CI: 1.21 to 1.38]; and high-risk
odds ratio: 1.30 [95% confidence interval: 1.23 to 1.37]). Also, there was a narrowing in the guideline
adherence gap between low- and high-risk patients over time (p  0.0002).
Conclusions Although adherence to guideline-based care remains paradoxically lower in those MI patients at higher risk of
mortality and most likely to benefit from treatment, care is improving for eligible patients within all risk catego-
ries, and the gaps between low- and high-risk groups seem to be narrowing. (J Am Coll Cardiol 2011;58:
1760–5) © 2011 by the American College of Cardiology Foundation
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based care of patients with acute coronary syndromes im-
proves their subsequent outcomes (1). Highest-risk patients
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and this has been termed the “risk–treatment paradox”
(3–5). This paradox may reflect accurate recognition of
higher-risk patients but not prescribing therapy out of
concern of adverse events with treatment; not prescribing
due to knowledge gaps regarding guideline recommenda-
tions; or absolute contraindications being present but not
documented. Alternatively, the paradox may reflect difficul-
ties physicians face in estimating mortality risk. Although
adherence to guideline-based treatment in hospitals across
the United States has been improving every year (6,7),
whether such improvement has occurred uniformly or is
only confined to lower-risk patients has never been examined.
GWTG–CAD (Get With The Guidelines–Coronary
Artery Disease) is a national performance improvement
program and registry that collects information on the
clinical characteristics, guideline-based therapy adherence,
and outcomes across the spectrum of clinical care in the
United States. Using this registry, we evaluated the follow-
ing: 1) whether the application of guideline-based care
among myocardial infarction (MI) patients remains subop-
timal in patients at a higher baseline risk; and 2) whether
there is a significant temporal change in the application of
guideline-based therapies in each risk group.
Methods
Details regarding the GWTG-CAD database, selection of
the study patients, development/validation of a risk strati-
fication model, and detailed statistical analysis have been
described in an online attachment (Online Appendix).
Results
Sample characteristics. The cohort included 112,848 MI
patients enrolled in GWTG from 279 sites between August
15, 2000, and December 30, 2008 (Fig. 1). Using the
previously described risk prediction model, patients were
classified into 3 tertiles of increasing risk: 36,541 (33.3%)
classified as low risk; 36,542 (33.3%) as intermediate risk;
and the remaining 36,541 (33.3%) as high risk. Although
high-risk patients were more likely to be older, female, and
have multiple medical comorbidities, they had better initial
lipid and glycemic profiles (Online Table 1). High-risk
patients were hospitalized longer (median length of stay 5
days), were less likely to be discharged home, and were more
likely to die during their hospitalization (Online Table 2)
than lower-risk patients.
Adherence to quality and performance measures. After
adjusting for various confounders, higher-risk patients were
less likely to receive aspirin and beta-blockers within 24 h of
presentation, were less likely to have their low-density
lipoprotein (LDL) values recorded or receive lipid-lowering
agents, and usually were revascularized/thrombolysed after
greater delay (ST-segment elevation myocardial infarction
[STEMI]/left bundle branch block patients) compared with
lower-risk MI patients. At discharge, eligible higher-riskpatients were also less likely to
receive aspirin, angiotensin-
converting inhibitors/angiotensin
receptor blockers, and beta-blockers
(all p  0.001). Moreover, these
patients were less likely to have
a last recorded blood pressure
140/90 mm Hg (odds ratio
[OR]: 0.60 [95% confidence in-
terval (CI): 0.56 to 0.64]), were
less likely to have received smok-
ing cessation counseling (OR:
0.41 [95% CI: 0.35 to 0.47]), and were less likely to have
attained 100% compliance with quality/performance mea-
sures (OR: 0.60 [95% CI: 0.55 to 0.65]) (Online Tables 3,
4, and 5).
Temporal trends in performance/quality measures.
From 2002 to 2008, a progressive increase in adherence
to all quality and performance measures was observed
(yearly adjusted composite performance measure increase
low-risk OR: 1.33 [95% CI: 1.22 to 1.45]; intermediate-
risk OR: 1.30 [95% CI: 1.21 to 1.38]; and high-risk OR:
1.30 [95% CI: 1.23 to 1.37]) (Fig. 2). The most notable
improvement in quality measures was seen in smoking
cessation advice given to current smokers at discharge
(low-risk OR: 1.76 [95% CI: 1.53 to 2.03]; intermediate-
risk OR: 1.70 [95% CI: 1.49 to 1.94]; high-risk OR: 1.62
[95% CI: 1.45 to 1.80]) and the least improvement was
Figure 1 Study Population
The study patient selection process described in detail. GWTG–CAD  Get With
The Guidelines–Coronary Artery Disease; NSTEMI  non–ST-segment elevation
myocardial infarction; STEMI  ST-segment elevation myocardial infarction.
Abbreviations
and Acronyms
CI  confidence interval
LDL  low-density
lipoprotein
MI  myocardial infarction
OR  odds ratio
STEMI  ST-segment
elevation myocardial
infarction
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patients with an LDL value 100 mg/dl (low-risk OR:
1.25 [95% CI: 1.18 to 1.32]; intermediate-risk OR: 1.18
[95% CI: 1.12 to 1.25]; high-risk OR: 1.22 [95% CI:
1.15 to 1.30]) (Online Table 5). Although the adherence
to each of these measures remained significantly lower in
the higher-risk MI group, the difference between the
low- and high-risk groups decreased significantly with
each passing year since 2003 (p  0.0002). Although
Figure 2 Temporal Trends in Performance/Quality Measures
Temporal trends in adherence to quality and performance measures in patients pre
converting enzyme (ACE) inhibitors, aspirin, and beta-blockers. (B) Acute measure
(C) Composite measures. ARB  angiotensin receptor blocker; LVSD  left ventrithese trends remained similar among patients presentingwith STEMIs, there were differences in patients with
non-STEMIs. When analyzed separately, the temporal
trends for all measures showed significant improvement
among men and women. Although some of improvement
in trend was due to better documentation of contraindi-
cations, temporal improvement in adherence to aspirin,
angiotensin-converting enzyme inhibitors/angiotensin
receptor blockers, and lipid-lowering agents at discharge
persisted among eligible patients in high-risk groups (Online
g with a myocardial infarction are shown. (A) Discharge measures for angiotensin-
piring and discharge measures for smoking cessation and lipid-lowering therapy.
ystolic dysfunction. Continued on next page.sentin
for as
cular sTable 6, Online Fig. 1).
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The principal findings of our study are 2-fold: 1) patients
with a higher baseline risk profile hospitalized with an MI
remain less likely to receive guideline-based care during
hospitalization; and 2) over time, there has been substantial
improvement in the adherence to guideline-recommended
therapies in all patients admitted with an MI within the
GWTG–CAD program.
This “risk–treatment paradox” wherein higher-risk pa-
tients are less likely to receive guideline recommended
therapies has been described previously (3,5,8–10). If treat-
ment decisions were well calibrated, patients at higher risk
for clinical events would be more—not less—likely to
Figure 2 Continuedreceive evidence-based therapies. We speculate that certain dinvasive/aggressive in-hospital therapies may have been
withheld from higher-risk patients out of genuine concern
of the risk of adverse effects in high-risk patients. This
concern has been somewhat addressed by Eagle et al. (1),
ho observed no increase in treatment-related adverse
ffects after the implementation of the Guidelines Applied
n Practice program in Michigan. This does not explain the
nderutilization of low-risk therapies (e.g., lipid-lowering
gents, aspirin) or other performance measures without any
dverse effects (e.g., measurement of LDL, counseling)
uring hospitalization and at discharge in our population.
McAlister et al. (4) suggest that physicians were likely to
ncounter confounding clinical/functional variables such as
epression or poor functional capacity in their routine
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such as ours and not assessed in suggested bedside risk
scores, but suggested by the greater prevalence of higher-
risk patients being discharged to a skilled nursing facility
(Online Table 2). Clinicians perhaps preferentially avoided
preventive therapies (such as statins) in patients who were
depressed or had a poor functional status out of the fear of
noncompliance/nonadherence to prescribed medications or
had planned to initiate some of these in the nursing facility
post-discharge. This pre-judgment by physicians of non-
compliance in elderly patients with cognitive, functional,
and social decline is logical. However, these same factors
also seem to portend a higher risk of future events in such
patients. Previous evidence suggests even higher rates of
noncompliance among elderly patients with increased sever-
ity of cardiac illness (11). It has also been suggested that
physicians may be concerned about applying evidence from
clinical trials (which usually exclude higher-risk patients) to
Figure 2 Continued
Composite performance measure: this calculation, developed by CMS, gives hosp
the number of times patients received GWTG performance interventions and dividi
Calculations are as follows: number receiving discharge ASA  number receiving e
(LVSD patients only  number receiving discharge smoking counseling  number
eligible early ASA  number eligible discharge BB  number eligible discharge AC
eligible discharge lipid-lowering therapy. Defect free measure: this measure shows
i.e. the percentage of “defect-free” care.their everyday practice. Although such concerns are wellfounded, these cardiovascular preventive therapies have
conferred benefits, more so in higher-risk populations ex-
cluded from trials such as those with depression or poor
functional capacity (11,12). The underuse of statins and
beta-blockers noted in our study in the higher-risk group
may be partly explained by these factors.
Encouragingly, however, our study revealed that over time,
guideline-based care has improved for all risk groups of
patients presenting with an MI. The implementation of
recommended guidelines continues to lag behind among the
higher-risk population, but the trends are encouraging. Al-
though similar trends have been reported earlier by the CRU-
SADE investigators (13), our study, to the best of our
knowledge, demonstrates for the first time the gradual oblit-
eration of this risk–treatment paradox. Perhaps this finding
may be an effect of participating in the GWTG and the ability
to obtain instant feedback and implementation of various
quality measures over time or better documentation of contra-
sense of their overall average performance. Scores are calculated by counting
sum by the total number of interventions for which these patients were eligible.
SA  number receiving discharge BB  number receiving discharge ACE/ARB
ing discharge lipid-lowering therapy  number eligible discharge ASA  number
(LVSD patients only  number eligible discharge smoking counseling  number
percentage of patients receive all interventions for which they are eligible,itals a
ng the
arly A
receiv
E/ARB
whatindications to certain therapies over time (Online Table 6).
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ticing clinician taking care of these patients as well as to
healthcare policy makers. As highlighted earlier, the exis-
tence of the risk–treatment paradox must be kept in mind
when practitioners feel the reluctance to initiate/continue
therapies to patients presenting with an MI. Whenever
possible, objective data should be used to carefully weigh
risks and benefits before withholding evidence-based ther-
apies in these patients. For policymakers, it is noteworthy
that hospitals participating in quality improvement projects
such as the GWTG have been shown to have superior acute
cardiac care and secondary prevention measures perfor-
mance that is sustained over time, compared with hospitals
not participating in this program (14). Perhaps one may
consider participation in such programs mandatory or even
linking the pay-for-performance method to participation in
such programs. Moreover, although the Centers for Medi-
care & Medicaid Services and other federal agencies have
been collecting data on similar measures, our data suggest
that over time, the adherence to all of these measures has
significantly improved among all risk groups. In addition,
more stringent process care measures may be implemented
and monitored, especially among the high-risk groups, to
sustain and build on the achievements attained thus far.
There are limitations to this study as noted in the Online
Appendix.
These results re-enforce that programs such as GWTG,
which provide solid science in the form of clearly articu-
lated, easily actionable items that physicians at the bedside
can adapt, lead to improved adherence to guideline-based
care in all risk groups and could be used in managing other
conditions and similar conditions in non-U.S. centers.
Conclusions
Although adherence to guideline-based care remained par-
adoxically lower in those MI patients at higher risk of
mortality and most likely to benefit from treatment, care is
improving for eligible patients within all risk categories, and
the gaps between low- and high-risk groups seem to be
narrowing.
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APPENDIX
For an expanded Study Methods and Study Limitations as well as supplemental
tables and figures, please see the online version of this article.
